[1,3] dioxolo [4,5-g] quinoline-6(5h)thione derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
US-2015344491-A1 · Dec 3, 2015 · US
Fourth-generation EGFR tyrosine kinase inhibitor
US11286261B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11286261-B2 |
| Application number | US-201816497917-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 29, 2018 |
| Priority date | Mar 29, 2017 |
| Publication date | Mar 29, 2022 |
| Grant date | Mar 29, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a compound having a tyrosine kinase inhibitory activity specific to C797S resistant mutant EGFR (particularly C797S tertiary-resistant mutant EGFR) and is useful as a C797S resistant mutant EGFR (particularly C797S mutant tertiary-resistant EGFR) specific tyrosine kinase inhibitor, an agent for preventing and/or treating non-small cell lung cancer with resistance mutant EGFR and the like, and the like.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound represented by the formula (I): wherein X is O or NH, R 1 and R 2 are each independently a hydrogen atom or an amino substituted hydrocarbon group, wherein the amino group is optionally mono- or di-substituted by C 1-6 alkyl group or guanidino group, R 3 and R 4 are each a hydrogen atom, and R 5 and R 6 are each independently a hydrocarbon group, excluding the following compound: or a salt thereof. 2. A method for inhibiting C797S resistant mutant EGFR tyrosine kinase activity, the method comprising contacting a cell expressing C797S resistant mutant EGFR with a compound or salt of claim 1 . 3. A method for treating non-small cell lung cancer in a subject in need thereof, the method comprising administering to the subject a compound or salt of claim 1 . 4. The method of claim 3 , wherein the non-small cell lung cancer is associated with C797S resistant mutant EGFR. 5. The compound of claim 1 , wherein the compound of formula (I) is or a salt thereof. 6. The compound of claim 1 , wherein the compound of formula (I) is
Assignees
Inventors
Classifications
- C07D491/147Primary
the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom · CPC title
Ortho-condensed systems · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the respiratory system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11286261B2 cover?
- Provided is a compound having a tyrosine kinase inhibitory activity specific to C797S resistant mutant EGFR (particularly C797S tertiary-resistant mutant EGFR) and is useful as a C797S resistant mutant EGFR (particularly C797S mutant tertiary-resistant EGFR) specific tyrosine kinase inhibitor, an agent for preventing and/or treating non-small cell lung cancer with resistance mutant EGFR and the…
- Who is the assignee on this patent?
- Univ Nagasaki, Univ Iwate Medical, Japanese Found For Cancer Res
- What technology area does this patent fall under?
- Primary CPC classification C07D491/147. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).